Skip to content

Study · Measured the body's own peptide · 1983

3 results

Increased circulation of T lymphocytes bearing surface thymosin alpha 1 in patients with myasthenia gravis: effect of thymectomy.

Dalakas MC, Rose JW, Paul J, Engel WK, McClure JE, Goldstein AL

Neurology1 Feb 1983Cited by 20 (Europe PMC)

PMID6337347 (opens in a new tab)DOI10.1212/wnl.33.2.144 (opens in a new tab)PepBankPUB-06337347
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with symptomatic myasthenia gravis, eleven of 16 had an increased number of T lymphocytes bearing the body's own surface thymosin alpha‑1.

    In plain wordsIn patients with symptomatic myasthenia gravis, most had more T cells carrying the body's own thymosin alpha‑1 on their surface.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseT lymphocytes bearing surface thymosin alpha 1 in symptomatic MG
    Study

    n = 16

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Eleven of 16 patients with symptomatic MG had an increased number of T lymphocytes bearing surface thymosin alpha 1 (T alpha 1)
    1 context sentence
    Summary · context
    We studied the interaction of the thymic hormone thymosin alpha 1 with peripheral blood B and T lymphocytes in patients with myasthenia gravis (MG), using antibodies against thymosin alpha 1 in an immunofluorescence technique.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In six young adults with symptomatic myasthenia gravis who responded to thymectomy, the number of cells bearing the body's own surface thymosin alpha‑1 returned to normal 1 month after surgery.

    In plain wordsIn six young adults with myasthenia gravis who responded to thymus removal, T cells carrying the body's own thymosin alpha‑1 returned to normal.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseT alpha 1 cell number after thymectomy
    Study

    n = 6

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In six young adults with symptomatic MG who subsequently responded to thymectomy, the number of T alpha 1 cells returned to normal 1 month after thymectomy.
    1 context sentence
    Summary · context
    We studied the interaction of the thymic hormone thymosin alpha 1 with peripheral blood B and T lymphocytes in patients with myasthenia gravis (MG), using antibodies against thymosin alpha 1 in an immunofluorescence technique.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In patients with asymptomatic myasthenia gravis, levels of T lymphocytes bearing the body's own surface thymosin alpha‑1 were normal.

    In plain wordsIn patients with myasthenia gravis without symptoms, T cells carrying the body's own thymosin alpha‑1 were at normal levels.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeT lymphocytes bearing surface thymosin alpha 1 in asymptomatic MG
    Study

    n = 5

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    5 patients with asymptomatic disease had normal levels of T alpha 1.
    1 context sentence
    Summary · context
    We studied the interaction of the thymic hormone thymosin alpha 1 with peripheral blood B and T lymphocytes in patients with myasthenia gravis (MG), using antibodies against thymosin alpha 1 in an immunofluorescence technique.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.